Follicum AB (Spotlight:FOLLI), a Swedish developer of drug candidates based on tissue repairing peptides, reported on Wednesday that the European Patent Office (EPO) has approved patent number EP 3,618,845 B1, relating to the company's novel peptides that are being developed to treat diabetes.
This follows the EPO's provisional approval announced in March 2020.
The new patent provides protection for the company's peptides and their use to treat diabetes in Europe until 2038.
Similar patents have previously been approved in the United States. Follicum also has a corresponding patent application under review by authorities in China, Japan, India, Canada, South Korea, Singapore, Israel and Australia.
Diamyd Medical granted US FDA Fast Track designation for Diamyd diabetes treatment
Aprecia names new chief commercial officer
Insulet's Omnipod 5 integration with Abbott FreeStyle Libre 2 Plus Sensor secures CE Mark approval
Kyowa Kirin enrols first subject in phase two tivozanib eye drops (KHK4951) clinical trial
Novo Nordisk to boost manufacturing capacity with acquisition of three fill-finish sites
Breye Therapeutics commences phase 1b/2a danegaptide clinical trial
DexCom Inc breaks ground on new manufacturing facility in Ireland
VibroSense Dynamics AB secures provisional patent for chemotherapy-induced nerve damage prediction
Innovent Biologics signs collaboration agreement with Sanegene Bio USA
Japan approves GSK's filing for Arexvy vaccination for at-risk adults
Arecor Therapeutics plc extends collaboration with Eli Lilly
OptiBiotix Health partners with Ravenswood for SlimBiome distribution in Australia and New Zealand
Boehringer Ingelheim granted European approval of oral liquid medication for feline diabetes